V., Dubynin, V
The Dulaglutide segment dominated the market with a share of 36.84% in 2025 due to its strong clinical efficacy, convenient once-weekly dosing schedule, proven cardiovascular benefits, and extensive physician adoption across diabetes treatment programs
Kuefer MU, Moinuddin M, Heidemann RL, Lustig RH, Rose SR, Burstein SR, Van Middlesworth L, Fleming I, Jenkins JJ, Shearer PD: Papillary thyroid carcinoma: demographics, treatment, and outcome in eleven pediatric patients treated at a single institution
Environmental factors, stress, and aging also contribute to its decline
p -value 0.3909]) was not associated with significant increased risk of flatulence, as shown in Fig